Newsroom.

A New Manufacturing Process to Remove Thrombogenic Factors (II, VII, IX, X, and XI) from Intravenous Immunoglobulin Gamma Preparations was accepted for poster presentation at the IgNS 2019 Conference. The national conference, attended by over 700 healthcare experts, was held at the Red Rock Casino Resort & Spa on October 24-27, 2019 in Las Vegas, NV. Dr. Alan Huber, PharmD, Director of Medical Affairs for GC Biopharma USA, Inc., presented GC’s manufacturing process, an innovative method of removing thrombogenic factors from plasma proteins in IVIG formulations. The abstract is available here